Advertisement

Chemoprevention of Head and Neck Cancers

  • William N. WilliamJr.
  • Christopher H. Lieu
  • Scott M. Lippman

Abstract

The term “chemoprevention” in reference to cancer was introduced by Sporn in 1976 and was defined as the use of natural, synthetic, or biologic compounds to halt, reverse, or prevent the initial phase of carcinogenesis or the progression of neoplastic cells to cancer [1] . The following three key biologic features of malignant transformation support the development of chemopreventive strategies: it involves the multipath, multistep, and multifocal disruption of normal cellular function.

Keywords

Oral Cancer Allelic Imbalance Oral Leukoplakia Retinyl Palmitate Oral Epithelial Dysplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sporn MB, Dunlop NM, Newton DL et al (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338PubMedGoogle Scholar
  2. 2.
    Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRefGoogle Scholar
  3. 3.
    Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6:963–968PubMedCrossRefGoogle Scholar
  4. 4.
    Califano J, van der Riet P, Westra W et al (1996) Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56:2488–2492PubMedGoogle Scholar
  5. 5.
    Olsen JH (1985) Second cancer following cancer of the respiratory system in Denmark, 1943–80. Natl Cancer Inst Monogr 68:309–324PubMedGoogle Scholar
  6. 6.
    Cooper JS, Pajak TF, Rubin P et al (1989) Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 17:449–456PubMedCrossRefGoogle Scholar
  7. 7.
    Licciardello JT, Spitz MR, Hong WK (1989) Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radiat Oncol Biol Phys 17:467–476PubMedCrossRefGoogle Scholar
  8. 8.
    Christensen PH, Joergensen K, Munk J et al (1987) Hyperfrequency of pulmonary cancer in a population of 415 patients treated for laryngeal cancer. Laryngoscope 97:612–614PubMedCrossRefGoogle Scholar
  9. 9.
    Tepperman BS, Fitzpatrick PJ (1981) Second respiratory and upper digestive tract cancers after oral cancer. Lancet 2:547–549PubMedCrossRefGoogle Scholar
  10. 10.
    Ecimovic P, Pompe-Kirn V (2002) Second primary cancers in laryngeal cancer patients in Slovenia, 1961–1996. Eur J Cancer 38:1254–1260PubMedCrossRefGoogle Scholar
  11. 11.
    Jang SJ, Chiba I, Hirai A et al (2001) Multiple oral squamous epithelial lesions: are they genetically related? Oncogene 20:2235–2242PubMedCrossRefGoogle Scholar
  12. 12.
    Worsham MJ, Wolman SR, Carey TE et al (1995) Common clonal origin of synchronous primary head and neck squamous cell carcinomas: analysis by tumor karyotypes and fluorescence in situ hybridization. Hum Pathol 26:251–261PubMedCrossRefGoogle Scholar
  13. 13.
    Bedi GC, Westra WH, Gabrielson E et al (1996) Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56:2484–2487PubMedGoogle Scholar
  14. 14.
    Scholes AG, Woolgar JA, Boyle MA et al (1998) Synchronous oral carcinomas: independent or common clonal origin? Cancer Res 58:2003–2006PubMedGoogle Scholar
  15. 15.
    Lydiatt WM, Anderson PE, Bazzana T et al (1998) Molecular support for field cancerization in the head and neck. Cancer 82:1376–1380PubMedCrossRefGoogle Scholar
  16. 16.
    Bhutani M, Pathak AK, Fan YH et al (2008) Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila Pa) 1:39–44CrossRefGoogle Scholar
  17. 17.
    William WN, Heymach JV, Kim ES et al (2009) Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 8(3):213–225PubMedCrossRefGoogle Scholar
  18. 18.
    O’Shaughnessy JA, Kelloff GJ, Gordon GB et al (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314–346PubMedGoogle Scholar
  19. 19.
    Kelloff GJ, Lippman SM, Dannenberg AJ et al (2006) Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin Cancer Res 12:3661–3697PubMedCrossRefGoogle Scholar
  20. 20.
    Warnakulasuriya S, Johnson NW, van der Waal I (2007) Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36:575–580PubMedCrossRefGoogle Scholar
  21. 21.
    Mehta FS, Shroff BC, Gupta PC et al (1972) Oral leukoplakia in relation to tobacco habits. A ten-year follow-up study of Bombay policemen. Oral Surg Oral Med Oral Pathol 34:426–433CrossRefGoogle Scholar
  22. 22.
    Silverman S, Bhargava K, Smith LW et al (1976) Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer 38:1790–1795PubMedCrossRefGoogle Scholar
  23. 23.
    Gupta PC, Mehta FS, Daftary DK et al (1980) Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 8:283–333PubMedCrossRefGoogle Scholar
  24. 24.
    Pindborg JJ, Roed-Peterson B, Renstrup G (1972) Role of smoking in floor of the mouth leukoplakias. J Oral Pathol 1:22–29PubMedCrossRefGoogle Scholar
  25. 25.
    Banoczy J, Sugar L (1975) Progressive and regressive changes in Hungarian oral leukoplakias in the course of longitudinal studies. Community Dent Oral Epidemiol 3:194–197PubMedCrossRefGoogle Scholar
  26. 26.
    Silverman S Jr, Gorsky M, Lozada F (1984) Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 53:563–568Google Scholar
  27. 27.
    Petti S (2003) Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol 39:770–780PubMedCrossRefGoogle Scholar
  28. 28.
    Einhorn J, Wersall J (1967) Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa. Cancer 20:2189–2193PubMedCrossRefGoogle Scholar
  29. 29.
    Banoczy J, Sugar L (1972) Longitudinal studies in oral leukoplakias. J Oral Pathol 1:265–272PubMedCrossRefGoogle Scholar
  30. 30.
    Roed-Peterson B (1971) Cancer development in oral leukoplakia follow-up of 331 patients. J Dent Res 50:711 (abstract 720)Google Scholar
  31. 31.
    Banoczy J (1977) Follow-up studies in oral leukoplakia. J Maxillofac Surg 5:69–75PubMedCrossRefGoogle Scholar
  32. 32.
    Schepman KP, van der Meij EH, Smeele LE et al (1998) Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 34:270–275PubMedGoogle Scholar
  33. 33.
    Lind PO (1987) Malignant transformation in oral leukoplakia. Scand J Dent Res 95:449–455PubMedGoogle Scholar
  34. 34.
    Kramer IR, El-Labban N, Lee KW (1978) The clinical features and risk of malignant transformation in sublingual keratosis. Br Dent J 144:171–180PubMedCrossRefGoogle Scholar
  35. 35.
    Holmstrup P, Vedtofte P, Reibel J et al (2006) Long-term treatment outcome of oral premalignant lesions. Oral Oncol 42:461–474PubMedCrossRefGoogle Scholar
  36. 36.
    Reibel J (2003) Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 14:47–62PubMedCrossRefGoogle Scholar
  37. 37.
    Pindborg JJ, Jolst O, Renstrup G et al (1968) Studies in oral leukoplakia: a preliminary report on the period pervalence of malignant transformation in leukoplakia based on a follow-up study of 248 patients. J Am Dent Assoc 76:767–771PubMedGoogle Scholar
  38. 38.
    Pindborg JJ, Renstrup G, Poulsen HE et al (1963) Studies in oral leukoplakias. V. Clinical and histologic signs of malignancy. Acta Odontol Scand 21:407–414CrossRefGoogle Scholar
  39. 39.
    Gupta PC, Bhonsle RB, Murti PR et al (1989) An epidemiologic assessment of cancer risk in oral precancerous lesions in India with special reference to nodular leukoplakia. Cancer 63:2247–2252PubMedCrossRefGoogle Scholar
  40. 40.
    Saito T, Yamashita T, Notani K et al (1995) Flow cytometric analysis of nuclear DNA content in oral leukoplakia: relation to clinicopathologic findings. Int J Oral Maxillofac Surg 24:44–47PubMedCrossRefGoogle Scholar
  41. 41.
    Napier SS, Cowan CG, Gregg TA et al (2003) Potentially malignant oral lesions in Northern Ireland: size (extent) matters. Oral Dis 9:129–137PubMedCrossRefGoogle Scholar
  42. 42.
    Bagan JV, Jimenez Y, Sanchis JM et al (2003) Proliferative verrucous leukoplakia: high incidence of gingival squamous cell carcinoma. J Oral Pathol Med 32:379–382PubMedCrossRefGoogle Scholar
  43. 43.
    Hansen LS, Olson JA, Silverman S Jr (1985) Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol 60:285–298CrossRefGoogle Scholar
  44. 44.
    Silverman S Jr, Gorsky M (1997) Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:154–157PubMedCrossRefGoogle Scholar
  45. 45.
    Zakrzewska JM, Lopes V, Speight P et al (1996) Proliferative verrucous leukoplakia: a report of ten cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82:396–401PubMedCrossRefGoogle Scholar
  46. 46.
    Shafer WG, Waldron CA (1961) A clinical and histopathologic study of oral leukoplakia. Surg Gynecol Obstet 112:411–420Google Scholar
  47. 47.
    Mehta FS, Pindborg JJ, Gupta PC et al (1969) Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. Cancer 24:832–849PubMedCrossRefGoogle Scholar
  48. 48.
    Kaugars GE, Burns JC, Gunsolley JC (1988) Epithelial dysplasia of the oral cavity and lips. Cancer 62:2166–2170PubMedCrossRefGoogle Scholar
  49. 49.
    Pindborg JJ, Daftary DK, Mehta FS (1977) A follow-up study of sixty-one oral dysplastic precancerous lesions in Indian villagers. Oral Surg Oral Med Oral Pathol 43:383–390PubMedCrossRefGoogle Scholar
  50. 50.
    Burkhardt A, Maerker R (1978) Dysplasieklassifikation oraler leukoplakien und präkanzerosen. Bedeutung für prognose und therapie. Dtsch Z Mund Kiefer Gesichtschir 2:199–205Google Scholar
  51. 51.
    Lee JJ, Hong WK, Hittelman WN et al (2000) Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6:1702–1710PubMedGoogle Scholar
  52. 52.
    Cruz IB, Snijders PJ, Meijer CJ et al (1998) p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 184:360–368PubMedCrossRefGoogle Scholar
  53. 53.
    Pindborg JJ, Reibel J, Holmstrup P (1985) Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol 14:698–708PubMedCrossRefGoogle Scholar
  54. 54.
    Abbey LM, Kaugars GE, Gunsolley JC et al (1995) Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80:188–191PubMedCrossRefGoogle Scholar
  55. 55.
    Karabulut A, Reibel J, Therkildsen MH et al (1995) Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 24:198–200PubMedCrossRefGoogle Scholar
  56. 56.
    Spitz MR, Etzel CJ, Dong Q et al (2008) An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila Pa) 1:250–254CrossRefGoogle Scholar
  57. 57.
    Mao L, Lee JS, Fan YH et al (1996) Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2:682–685PubMedCrossRefGoogle Scholar
  58. 58.
    Partridge M, Emilion G, Pateromichelakis S et al (1998) Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol 34:77–83PubMedCrossRefGoogle Scholar
  59. 59.
    Partridge M, Pateromichelakis S, Phillips E et al (2000) A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 60:3893–3898PubMedGoogle Scholar
  60. 60.
    Rosin MP, Cheng X, Poh C et al (2000) Use of allelic loss to predict malignant risk for lowgrade oral epithelial dysplasia. Clin Cancer Res 6:357–362PubMedGoogle Scholar
  61. 61.
    Rosin MP, Lam WL, Poh C et al (2002) 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 62:6447–6450PubMedGoogle Scholar
  62. 62.
    Donnellan R, Chetty R (1998) Cyclin D1 and human neoplasia. Mol Pathol 51:1–7PubMedCrossRefGoogle Scholar
  63. 63.
    Zhou P, Jiang W, Weghorst CM et al (1996) Overexpression of cyclin D1 enhances gene amplification. Cancer Res 56:36–39PubMedGoogle Scholar
  64. 64.
    Wang TC, Cardiff RD, Zukerberg L et al (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669–671PubMedCrossRefGoogle Scholar
  65. 65.
    Papadimitrakopoulou VA, Izzo J, Mao L et al (2001) Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 7:3127–3134PubMedGoogle Scholar
  66. 66.
    Izzo JG, Papadimitrakopoulou VA, Liu DD et al (2003) Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 95:198–205PubMedCrossRefGoogle Scholar
  67. 67.
    Alt JR, Cleveland JL, Hannink M et al (2000) Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102–3114PubMedCrossRefGoogle Scholar
  68. 68.
    Diehl JA, Cheng M, Roussel MF et al (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499–3511PubMedCrossRefGoogle Scholar
  69. 69.
    Diehl JA, Zindy F, Sherr CJ (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11:957–972PubMedCrossRefGoogle Scholar
  70. 70.
    Papadimitrakopoulou V, Izzo JG, Liu DD et al (2009) Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila Pa) 2:14–21CrossRefGoogle Scholar
  71. 71.
    Szabo E (2008) Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy. Cancer Prev Res (Phila Pa) 1:312–315CrossRefGoogle Scholar
  72. 72.
    Papadimitrakopoulou VA, Lee JJ, William WN Jr et al (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599–604PubMedCrossRefGoogle Scholar
  73. 73.
    Mao L, El-Naggar AK, Papadimitrakopoulou V et al (1998) Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 90:1545–1551PubMedCrossRefGoogle Scholar
  74. 74.
    Hong WK, Endicott J, Itri LM et al (1986) 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501–1505PubMedCrossRefGoogle Scholar
  75. 75.
    Stich HF, Hornby AP, Mathew B et al (1988) Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40:93–101PubMedCrossRefGoogle Scholar
  76. 76.
    Stich HF, Rosin MP, Hornby AP et al (1988) Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 42:195–199PubMedCrossRefGoogle Scholar
  77. 77.
    Sankaranarayanan R, Mathew B, Varghese C et al (1997) Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 33:231–236PubMedCrossRefGoogle Scholar
  78. 78.
    Lippman SM, Batsakis JG, Toth BB et al (1993) Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328:15–20PubMedCrossRefGoogle Scholar
  79. 79.
    Papadimitrakopoulou VA, Hong WK, Lee JS et al (1997) Low-dose isotretinoin versus betacarotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 89:257–258PubMedCrossRefGoogle Scholar
  80. 80.
    Chiesa F, Tradati N, Grigolato R et al (2005) Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 115:625–629PubMedCrossRefGoogle Scholar
  81. 81.
    Lippman SM, Lee JJ, Martin JW et al (2006) Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res 12:3109–3114PubMedCrossRefGoogle Scholar
  82. 82.
    William WN Jr, Lee JJ, Lippman SM et al (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2:22–26CrossRefGoogle Scholar
  83. 83.
    Mulshine JL, Atkinson JC, Greer RO et al (2004) Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 10:1565–1573PubMedCrossRefGoogle Scholar
  84. 84.
    Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ et al (2008) Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14:2095–2101PubMedCrossRefGoogle Scholar
  85. 85.
    Rudin CM, Cohen EE, Papadimitrakopoulou VA et al (2003) An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21:4546–4552PubMedCrossRefGoogle Scholar
  86. 86.
    Armstrong WB, Kennedy AR, Wan XS et al (2000) Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 6:4684–4691PubMedGoogle Scholar
  87. 87.
    Hong WK, Lippman SM, Itri LM et al (1990) Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801PubMedCrossRefGoogle Scholar
  88. 88.
    Benner SE, Pajak TF, Lippman SM et al (1994) Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term followup. J Natl Cancer Inst 86:140–141PubMedCrossRefGoogle Scholar
  89. 89.
    Bolla M, Lefur R, Van Ton J et al (1994) Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 30A:767–772CrossRefGoogle Scholar
  90. 90.
    van Zandwijk N, Dalesio O, Pastorino U et al (2000) EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92:977–986Google Scholar
  91. 91.
    Khuri FR, Lee JJ, Lippman SM et al (2006) Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98:441–450PubMedCrossRefGoogle Scholar
  92. 92.
    Mayne ST, Cartmel B, Baum M et al (2001) Randomized trial of supplemental beta-carotene to prevent second head and neck cancer. Cancer Res 61:1457–1463PubMedGoogle Scholar
  93. 93.
    Bairati I, Meyer F, Gelinas M et al (2005) A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst 97:481–488PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • William N. WilliamJr.
    • 1
  • Christopher H. Lieu
    • 1
  • Scott M. Lippman
    • 1
  1. 1.Department of Thoracic/Head and Neck Medical OncologyThe University of Texas M. D. Anderson Cancer CenterHouston, TXUSA

Personalised recommendations